Bacterial Infectious Diseases Therapeutics Market was valued at USD 75.8 billion in 2021. It is forecasted to reach USD million by 2029, growing at a CAGR of 8.2% during the forecast period (2022-2029). Bacterial infectious diseases are infectious diseases occurred due to bacteria that trigger a protective immune response. It involves the proliferation of a harmful strain of bacteria on or inside the body. Bacteria are the single-celled microorganisms found in all sorts of environments, including soil, water bodies, and in or on other bodies. Bacteria are present in different shapes including rod-shaped (bacilli), spherical (cocci), or helical (spirilla). Bacterial infectious diseases can affect the throat, lungs, skin, bowel and other body parts. Bacterial infectious diseases are characterized by various signs and symptoms including bloody urine, frequent urination, diarrhea, fatigue, fever, sore throat, headache, cough, aches, nausea, vomiting, rashes, lesions, abscesses, weakness, and others. Bacterial infectious diseases increase the risk of causing life-threatening complications, such as blood poisoning, kidney failure, toxic shock syndrome, and others.
As per DataM Intelligence, Bacterial Infectious Diseases Therapeutics Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Bacterial Infectious Diseases Therapeutics Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.
Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Bacterial Infectious Diseases Therapeutics Market in the United States and Canada produces the utmost share. Whereas the European Bacterial Infectious Diseases Therapeutics Market is projected to continue its presence globally during the period of 2022- 2029.
By Disease Type, By Therapeutics, By Route of Administration, By Distributional Channels, and By Region
Report Insights Covered
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
North America, Latin America, Europe, Middle East, Africa, Asia Pacific, and the Rest of the world.
Major Companies Covered
Abbott Laboratories, EKF Diagnostics Holdings plc, BioMérieux SA, Atlas Medical, Quidel Corporation, BIOSYNEX SA, Prestige Brands Holdings, Swiss Precision Diagnostics (SPD) GmbH, Piramal Enterprises, NG BIOTECH SAS, and among the major companies listed in the final report.
To know more insights into the Diagnostic Imaging Market, get our Sample Brochure
Growing Older Population is Driving the Growth of the Market
The demand for bacterial infectious diseases therapeutics is increasing with the rising older population as the older population is at a high risk of developing bacterial infectious diseases. Severe bacterial infectious diseases are observed among the older population due to several factors such as medical conditions, weakened immune system, concurrent use of different drugs, delayed diagnosis, delayed or diminished response to therapy.
According to the United Nations (UN) report, the older population of age-group 65 years or above was 727 million worldwide in 2020. The older population is expected to be more than double and reach up to 1.5 billion in 2050. Asia has a higher older population in comparison to Europe and Northern America. Urinary tract infections, skin infections, gastrointestinal infections, pneumonia, influenza, and others are most frequent among the older population.
Increasing Antibacterial Resistance is Expected to Boost the Development of Therapeutics over the Forecast Period.
There is growing antibacterial resistance due to the emergence and spread of drug-resistant pathogens. According to the World Health Organization (WHO)’s new Global Antimicrobial Surveillance System (GLASS), antibiotic resistance was observed among 500,000 people with suspected bacterial infections across 22 countries. Approximately, 86% of new TB cases in 30 high TB burden countries in 2020.
Several factors such as misuse and overuse of antibacterial, lack of access to clean water, sanitation and hygiene (WASH), poor infection and disease prevention and control in healthcare facilities, poor access to quality, affordable medicines, vaccines and diagnostics, lack of awareness and knowledge, and lack of enforcement of legislation are causing the antibacterial resistance. The antibacterial resistance is limiting the treatment of the most frequent bacterial infectious diseases. There is a rising spread of multi- and pan-resistant bacteria infections not being treatable by using the existing antibacterial worldwide. The increasing antibacterial resistance has resulted in the rising development of therapeutics for the treatment of bacterial infectious diseases. The pipeline of bacterial infectious diseases is robust with the involvement of several therapeutics being developed. Several companies are developing therapeutics that is effective in overcoming the resistance demonstrated by existing antibacterial. According to the World Health Organization (WHO), there are approximately 32 antibiotics in clinical development that address the WHO list of priority pathogens. Out of these 32 antibiotics in the pipeline, only six were classified as innovative.
Rising Organizations & Institutes Initiatives for Overcoming the Antibacterial Resistance is Fueling the Market Growth
Several organizations & institutes have raised initiatives for overcoming antibacterial resistance. For instance, The India government has launched a “National Programme on AMR Containment during the 12th five-year plan, which is coordinated by NCDC. This phased manner included 35 state medical college labs and 26 states/UT. World Health Organization (WHO) had entered into the Global Antibiotic Research and Development Partnership (GARDP) with the Drugs for Neglected Diseases Initiative (DNDi). This partnership aims at developing and delivering the five new treatments that target drug-resistant bacteria identified by WHO as posing the greatest threat by 2025.
The United States Food and Drug Administration (FDA) has passed the Generating Antibiotic Incentives Now (GAIN) act for addressing the public health threat of antibacterial drug resistance by stimulating the development and approval of new antibacterial and antifungal drugs.
COVID-19 Impact Analysis
The bacterial infectious diseases therapeutics has witnessed drastic growth with the increasing number of people suffering from the COVID-19 as the antibacterial are being used for the treatment of bacterial infections among the patients with COVID-19. Various bacteria species such as Staphylococcus spp., Enterococcus spp., Klebsiella pneumonia, Enterobacter spp., Escherichia coli, Acinetobacter spp., and Pseudomonas spp are causing the infection among the patients with COVID-19.
According to the Bradley J. Langford et.al., 2020 study published in clinical microbiology & infection (CMI), bacterial co-infection was observed among 3.5% of COVID-19 patients and 14.3% of COVID-19 patients. Approximately, 71.9% of COVID-19 patients received antibiotics for the treatment of bacterial infections. Antibiotics such as azithromycin, ceftriaxone, quercetin, rapamycin, doxycycline, and other antibiotics are mostly recommended among the patients. Azithromycin has demonstrated the anti-inflammatory effects that can be useful for reducing an overactive immune response to COVID-19.
According to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, the estimation that the prevalence of Rheumatoid Arthritis (RA) was resulted in 3.26 million in 2019. Women are two to three times as likely to be affected in comparison to men. It has been observed that around one in 12 women and one in 20 men would develop an inflammatory autoimmune rheumatic disease during their life. According to Giegerich E et.al. 2018, the diagnosed prevalence of Crohn’s Disease was 6 cases per 100,000 in lower-income Asia-Pacific, 46 cases per 100,000 in high-income Asia-Pacific, 133 cases per 100,000 in Europe, and 210 cases per 100,000 in North America in 2017. The diagnosed prevalence of Crohn’s Disease is highest among people of age-group 40-54 years. The prevalence of ankylosing spondylitis was observed to be 23.8 per 10,000 in Europe, 16.7 per 10,000 in Asia, 31.9 10,000 in North America, 10.2 10,000 in Latin America and 7.4 per 10,000 in Africa.
Beta-Lactam segment is expected to hold the largest share in the Bacterial Infectious Diseases Therapeutics market
By therapeutics, the market is classified as beta-lactam, quinolones, macrolides, tetracyclines, sulfonamide, and others. The Beta-lactam segment is anticipated to hold the largest share as it is the most prescribed antibacterial for the prevention & treatment of bacterial infection. The beta-lactam acts by inhibiting cell wall synthesis. It targets the penicillin-binding proteins (PBPs) involved in the cross-linking of the bacterial cell wall. β-Lactam antibiotics are effective against a broad range of clinical indications. Penicillin’s, cephalosporins, carbapenems, and monobactams are the beta-lactam antibacterial with the highest market penetration.
There is increasing research and development activities for beta-lactam therapeutics. For instance, in March 2019, Iterum Therapeutics had received Qualified Infectious Disease Product (QIDP) and Fast Track Designations from the United States Food and Drug Administration (FDA) for its oral and intravenous (IV) formulations of sulopenem in four new indications including the community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory disease. Sulopenem had also received the Qualified Infectious Disease Product (QIDP) and Fast Track Designations for the treatment of uncomplicated urinary tract infection (uUTI), complicated urinary tract infection (cUTI), and complicated intra-abdominal infection (cIAI).
By Distribution Channel, Retail Pharmacies Segment is Expected to Witness a High Growth Over the Forecast Period
The market is classified on the distribution channel as the hospital pharmacies, retail pharmacies, online pharmacies and others. The retail pharmacies are segmented to have the highest market growth due to the high availability of therapeutics for the treatment of bacterial infectious diseases in the retail pharmacies & drug stores. There is an increase in the number of retail stores across the globe. According to the cross-sectional survey, approximately 93.5% of antibiotics including amoxicillin and trimethoprim-sulfamethoxazole were prescribed by the majority of the registered drug shops.
North America region holds the largest market share global Bacterial Infectious Diseases Therapeutics market
North America region is dominating the global bacterial infectious diseases therapeutics market accounted for the largest market share in 2021 owing to the increasing prevalence of bacterial infectious diseases. According to the Centers for Disease Control and Prevention (CDC), the incidence cases of tuberculosis was 7,860 in the United States in 2021. The total number of incidence cases of salmonella and Lyme disease was 58,371 and 34,945 respectively in the United States in 2019. There is a growing prevalence of antibacterial resistant infections. According to the Centers for Disease Control and Prevention (CDC), every year more than 2.8 million people were affected by antibiotic-resistant infections 2019. Every year more than 35,000 people died due to antibiotic-resistant infections.
The United States accounts for the highest market share due to the higher usage of therapeutics for the treatment of bacterial infectious diseases. According to the Centers for Disease Control and Prevention (CDC), the healthcare providers had prescribed 270.2 million antibiotic prescriptions i.e., 836 antibiotic prescriptions per 1000 persons. There is rising approval & launch of therapeutics for the treatment of bacterial infectious diseases. For instance, on 4th June 2020, the United States Food and Drug Administration approved Recarbrio. The Recarbrio is to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in patients 18 years of age and older. The easy availabilities of the antibacterial shall stimulate the market growth over the forecasted period.
Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period
Asia-Pacific region is estimated to be the fastest-growing region in the global bacterial infectious disease therapeutics market owing to the increasing prevalence of bacterial infectious diseases with the increasing older population. According to the United Nations Report, there were around 87millions of the population of age-group 65 years or over in India. The increasing investment for the improvement of the healthcare facilities & infrastructure shall have a positive impact on the market.
There is increasing research and development activities for the development of therapeutics for the treatment of bacterial infectious diseases. There is a presence of several market players developing therapeutics for the treatment of bacterial infectious diseases. There is growing awareness regarding the use of antibacterial for the treatment of bacterial infection. The increasing domestic income and purchasing power of people shall boost the demand for bacterial infectious diseases therapeutics over the forecasted period.
The bacterial infectious diseases therapeutics market studied is a fragmented market with the presence of a large number of market players. Novartis AG, GlaxoSmithkline Plc, Pfizer Inc, Merck & Co., Inc., Sanofi, Allergan, Bayer AG, AstraZeneca Plc, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Johnson and Johnson, and Teva Pharmaceuticals Industries Ltd. are the major market players with the significant market share. Companies are adopting several growth strategies such as product approvals, product launches, acquisitions, mergers, collaborations, and licensing for increasing their market presence. For instance,
Mergers & Collaborations:
In July 2019, Nosopharm had entered into the collaboration with Evotec SE for advancing the NOSO-502, a novel antibiotic class against Enterobacteriace infections to the clinical stage of development and develop a second-generation Odilorhabdin for the treatment of hospital-acquired pneumonia and ventilation-associated pneumonia (HAP/VAP)
Product Launch & Approvals:
In July 2019, Merck & Co. had received approval from the United States Food and Drug Administration (FDA) for the Recarbrio (imipenem, cilastatin, and relebactam) injection, 1.25 grams, a new combination antibacterial. Recarbrio is recommended for the patients 18 years of age and older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible Gram-negative microorganisms such as Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumonia, and Pseudomonas aeruginosa.
In July 2019, Merck & Co. had received the approval for Zerbaxa (ceftolozane and tazobactam) from the United States Food and Drug Administration (FDA) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years and older.
Allergan plc had received the approval to expand the use of Avycaz (ceftazidime and avibactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by the following susceptible Gram-negative microorganisms including the Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Serratia marcescens, Proteus mirabilis, Pseudomonas aeruginosa, and Haemophilus influenza in patients 18 years of age or older.
On 19th August 2019, The United States Food and Drug Administration approved Xenleta to treat adults with community-acquired bacterial pneumonia. This new drug provides a better option for treating patients with community-acquired bacterial pneumonia.
In February 2020, Grifols had acquired the Aradigm, an antibiotic developer.
On 11th October 2021, Sandoz completed the acquisition of GSK’s cephalosporin business, confirming Sandoz's commitment to the antibiotics business.
Get your free sample proposal with a single click!